Site updated at Wednesday, 22 June 2016

Living with Dementia

Transdermal Rivastigmine

Drug Patch Gets OK for Severe Alzheimer’s

The FDA has expanded the indication for transdermal rivastigmine to include patients with severe Alzheimer’s disease.

The approval means that the transdermal agent is indicated for use in any Alzheimer’s patient, irrespective of disease stage or severity. The expanded indication is the first of its type for any Alzheimer’s drug, according to a statement… Drug Patch Gets OK for Severe Alzheimer’s   

Going Home (A short film on Dementia)

tasigna1 - paraphrenia1 - vitamin b-11 - ruth sutherland1 - eeg1 - journal of alzheimer's disease2 - amyloid1 - cognitive function9 - peanut butter1 - menopause1 - korsakoff amnesic syndrome1 - functional psychosis1 - structural imaging1 - low-density lipoprotein receptor-related protein 61 - immune globulin1 - reconceptualization1 - huntington’s disease2 - igfbp-31 - apoe gene3 - protein plaques1 - wks4 - alcoholic encephalopathy10 - dementia risk4 - arterial plaques1 - late-onset alzheimers disease1 - blast-induced traumatic brain injury1 - muscle co-ordination1 - mirna1 - gastrointestinal disorders1 - the journal of neuroscience1 -